- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback